Cargando…
Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215689/ https://www.ncbi.nlm.nih.gov/pubmed/30430023 http://dx.doi.org/10.1136/esmoopen-2018-000451 |
| _version_ | 1783368194222718976 |
|---|---|
| author | Parker, Chris |
| author_facet | Parker, Chris |
| author_sort | Parker, Chris |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6215689 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-62156892018-11-14 Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE Parker, Chris ESMO Open Podcast BMJ Publishing Group 2018-10-21 /pmc/articles/PMC6215689/ /pubmed/30430023 http://dx.doi.org/10.1136/esmoopen-2018-000451 Text en © Author (s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0 |
| spellingShingle | Podcast Parker, Chris Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE |
| title | Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE |
| title_full | Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE |
| title_fullStr | Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE |
| title_full_unstemmed | Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE |
| title_short | Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE |
| title_sort | report from the esmo 2018 presidential symposium—radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from stampede |
| topic | Podcast |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215689/ https://www.ncbi.nlm.nih.gov/pubmed/30430023 http://dx.doi.org/10.1136/esmoopen-2018-000451 |
| work_keys_str_mv | AT parkerchris reportfromtheesmo2018presidentialsymposiumradiotherapytotheprimarytumourformenwithnewlydiagnosedmetastaticprostatecancersurvivalresultsfromstampede |